Ragini Kudchadkar, MD, medical oncologist and melanoma specialist at Winship, has been named chair of Winship's Clinical and Translational Review Committee.
Ragini Kudchadkar, MD, medical oncologist and melanoma specialist at Winship Cancer Institute of Emory University (Winship), has been named chair of Winship's Protocol Review and Monitoring Committee (formerly Clinical and Translational Review Committee), the group responsible for scientifically reviewing all proposed cancer clinical trials at Winship.
Kudchadkar, an associate professor in the Department of Hematology and Medical Oncology, will begin her new role on Feb. 1, 2020. She succeeds Taofeek Owonikoko, MD, PhD, who was named co-leader of Winship's Discovery and Developmental Therapeutics Research Program in November 2019. Thomas Olson, MD, professor in the Department of Pediatrics, will remain as co-chair of Winship's Protocol Review and Monitoring Committee.
In her new role as chair, her responsibilities will include reviewing and prioritizing new clinical research proposals for scientific quality and merit and monitoring the progress of active clinical studies for accrual and scientific validity.
"I'm pleased to be named chair of this committee and to play a role in ensuring that Winship clinical trials are scientifically and statistically sound," said Kudchadkar. "Clinical trials go to the heart of Winship's research mission."
The Protocol Review and Monitoring Committee functions as a distinct, independent body from the Winship Clinical Trials Office and the Data Safety Monitoring Committee. The committee's overarching goal is to support and facilitate the conduct of Winship's clinical cancer research efforts.
